PCSC

PCSC is not an operating business — it is a Cayman Islands blank-check shell (incorporated March 22, 2024) whose entire $92.8M of assets is essentially the IPO trust account. The income statement confirms this: operating income is -$2.98M (pure corporate overhead), and the $837K of 'net income' is trust interest, not earnings. Stockholders' equity is -$4.80M and current liabilities exploded +969% to $2.25M against just $908K of current assets and $865K of cash outside trust — all normal SPAC mechanics (public shares sit in mezzanine, deal costs accrue), but it means there is no standalone fundamental case here whatsoever. On the numbers as a company, this is uninvestable.

The only thing that matters is the announced Business Combination with Freenome (signed Dec 5, 2025), which converts PCSC into 'New Freenome' at an implied base equity value of $725M, expected to close in the first half of 2026. As of today (June 30, 2026) that window is closing or just lapsed — yet the filing gives no Freenome financials, no revenue, no burn rate. Freenome is an early-stage cancer-screening / liquid-biopsy diagnostics company (consistent with the medical-laboratories SIC) being valued at three-quarters of a billion dollars on data this package does not contain. That is precisely the 'unknowable risk' the mandate flags: you cannot underwrite the forward entity from what is provided.